Then, WFA and glucose transport inhibitor (phloretin) treatment was introduced causing a dramatic reduction in tumor size, suggesting that the combination of WFA and metabolism targeting therapies could be an effective therapeutic strategy against EGFR resistant lung cancer [94]. The gene discussed is EGFR; the disease is lung cancer.